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A panel of 24 monoclonal antibodies (MAbs) was generated against human papillomavirus (HPV) types 16 and 18 L1
virus-like particles (VLPs). The MAbs were screened for reactivity to a variety of VLPs prepared from HPV-6, -11, -16, -18, -
31, -33, -35, and -45, cottontail rabbit papillomavirus, bovine papillomavirus type 1, and a set of 35 overlapping 20-amino-
acid peptides spanning the entire HPV-16 L1 gene. Type-specific linear and conformational surface epitopes were detected
as well as several cross-reactive linear epitopes that showed various levels of cross-reactivity between different genital
HPV and animal papillomavirus L1s. Most of the linear epitopes were mapped using synthetic peptides, and the epitopes
were identified as being either surface or buried within the VLP as defined by the pattern of reactivity in ELISA using intact
and disrupted VLP antigen. These MAbs may be useful reagents to help define neutralizing epitopes of HPV-16 and -18
when infectivity assays become available, and to define the regions of L1 that are exposed on the surface or buried within
the assembled capsid. q 1996 Academic Press, Inc.
INTRODUCTION the production of high-risk HPVs is the difficulty in dem-
onstrating the infectious nature of the prepared HPVs
Several human papillomavirus (HPV) types have been because of some poorly understood inefficiencies in HPV
strongly associated with a variety of genital malignancies infectivity models. To date, large quantities of infectious
and have been described as ‘‘high-risk’’ HPV types (De- virus have been prepared only for one of the low-risk
villiers, 1989; zur Hausen, 1991; Bosch et al., 1995). Diffi- HPV types (Kreider et al., 1985).
culties in obtaining infectious virus stocks of HPVs, espe- Several protein expression systems have demon-
cially the high-risk types, have hampered studies on the strated that virus-like particles (VLPs) of any HPV type
surface epitopes involved in defining neutralizing epi- can be produced (Zhou et al., 1991; Kirnbauer et al., 1992;
topes as well as viral sites that interact with host cell Hagensee et al., 1993; Sasagawa et al., 1995; Heino et
surfaces. Lesions induced by HPV-16 and HPV-18 con- al., 1995a), and these VLPs closely resemble infectious
tain lower amounts of infectious virus particles than le- particles by ultrastructural studies (Hagensee et al.,
sions containing some of the low-risk HPV types (Cubie,
1994). Because most high-risk HPV types have been iso-
1974; Kreider et al., 1985, 1990; Favre et al., 1975; Taich-
lated, cloned, and sequenced, large stocks of assembled
man et al., 1984). Several animal and cell culture systems
capsids of these types can now be easily prepared. One
have been developed which have provided methods to
additional advantage of papillomavirus (PV) VLPs is that
propagate infectious stocks of various HPVs including
they correctly assemble viral surface conformational
HPV-1 (Kreider et al., 1990), HPV-11 (Kreider et al., 1985;
structures that are involved in triggering virus-neutraliz-
Dollard et al., 1992), HPV-16 (Sterling et al., 1990; Brand-
ing antibodies (Kirnbauer et al., 1992; Rose et al., 1994;
sma et al., 1995), HPV-31 (Meyers et al., 1992), and sev-
Christensen et al., 1994a; Breitburd et al., 1995) as welleral epidermodysplasia verruciformis-associated HPVs
as in interactions with cell surfaces (Roden et al., 1994a;(Majewski et al., 1994). However, these systems have
Mu¨ller et al., 1995; Volpers et al., 1995). Viral structuresgenerated only limited quantities of infectious virus of
involved in cell-binding and the predominant virus-neu-the high-risk types, and the yields of virus have been
tralizing epitopes require fully assembled VLPs, andinsufficient for the production of surface reactive mono-
these structures have not been detected on capsid pro-clonal antibodies (MAbs). One further complication with
tein subunits, bacterially derived PV proteins or synthetic
peptides.
In this study we have prepared a panel of MAbs1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (717) 531-5634. against HPV-16 and HPV-18 L1 VLPs as probes to ana-
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lyze capsid surface and buried epitopes. A range of differ- pH 7.0 (Cowsert et al., 1987). VLP antigen was denatured
by alkaline treatment and reduction for 30 min at rooment type-specific and cross-reactive MAbs was pro-
duced. The epitopes of many of the MAbs were identified temperature in 0.2 M Na2CO3 buffer (pH 10.6) containing
0.01 M dithiothreitol (Favre et al., 1975). The denaturedusing synthetic peptides, and the epitope exposure on
intact and disrupted VLPs was determined. Several VLP antigen was dried onto ELISA plate wells by over-
night incubation at 377. MAb supernatants were testedMAbs recognizing conformationally dependent epitopes
were also generated. in duplicate at 1:50 dilution as previously described
(Christensen et al., 1990).
Thirty-five 20-amino-acid peptides, with a 5-amino-acidMATERIALS AND METHODS
overlap, representing the deduced amino acid sequence
Production of papillomavirus virus-like particles of the HPV-16 L1 ORF (Seedorf et al., 1985) were used
in a peptide ELISA as previously described (Dillner etVLPs of various human and animal PV types were
al., 1990). Under stringent ELISA conditions, the back-prepared using recombinant baculoviruses [HPV-6, -11,
ground OD readings were regularly 0.000, and positive-16, -18, and -31, cottontail rabbit PV (CRPV), and bovine
signals mostly greater than 2.0. The first of the 35 pep-PV type 1 (BPV-1)] and recombinant vaccinia viruses
tides for the HPV-16 began at the first methionine of the(HPV-16, -33, -35, and -45) as previously described (Ha-
open reading frame of L1 (Dillner et al., 1990). However,gensee et al., 1993; Kirnbauer et al., 1992; Christensen
the VLPs were prepared starting from the consensuset al., 1994a). VLPs for all of the above PV types contained
methionine for all PV L1s, which for HPV-16 and -18, isthe major coat protein, L1, only. VLPs were purified from
represented by the second and third methionine, respec-infected cells by CsCl gradient centrifugation and dia-
tively. Thus for peptide A16-2, only the latter 10 aminolyzed against phosphate-buffered saline (PBS) containing
acids (beginning from the consensus methionine) are0.5 M NaCl, then stored at 0707.
present in the L1 proteins contained in the HPV-16 L1
VLPs that were used for immunizations. Peptides repre-Production and screening of monoclonal antibodies
senting homologous regions of HPV-16 for other PV L1
MAbs reactive to HPV-16 and HPV-18 L1 VLPs were proteins were prepared by coalignment of amino acids
prepared as previously described (Christensen et al., beginning from the consensus methionine. Peptide ELI-
1990; Christensen et al., 1994b). Briefly, recombinant ba- SAs were prepared using 50 ml of each synthetic peptide
culovirus-induced HPV-16 or -18 L1 VLPs were purified (20 mg/ml in 0.1 M Tris/HCl buffer, pH 8.8) which were
from Sf9 insect cells by CsCl banding and used as immu- added to ELISA plate wells, then incubated at room tem-
nogen. VLPs (100 mg per mouse) were mixed with com- perature overnight. Wells were washed and blocked for
plete Freund’s adjuvant and injected subcutaneously into 60 min with PBS containing 10% horse serum, then plates
BALB/c mice. Two weeks after immunizations, the mice were washed followed by addition of 1:50 dilution of MAb
were sacrificed, and draining lymph node and spleen supernatants. After a further 1-hr incubation, horseradish
cells removed for fusion with the mouse myeloma fusion peroxidase-coupled anti-mouse antiserum was added,
partner P3X63-Ag8.653 as previously described (Chris- followed 1 hr later by substrate, and absorbances were
tensen et al., 1990). Supernatants from growing hybrido- recorded at 415 nm after 60-min development. A small
mas were screened for reactivity to intact and denatured number of additional 20-amino-acid peptides of several
HPV-16 or -18 L1 VLP, and positive wells cloned and human and animal PVs that represented homologous
retested. A total of 14 HPV-16 L1 VLP-reactive and 10 regions to the peptides of HPV-16 L1 were prepared also,
HPV-18 L1 VLP-reactive MAbs were selected for further and tested in the peptide ELISA as described above.
studies.
Sets of MAbs reactive to VLPs of HPV-31, -33, -35, Western blotting
and -45 were prepared in a similar manner to MAbs Selected MAbs that were reactive to denatured VLP by
reactive to HPV-16 and -18. Individual type-specific MAbs ELISA were tested for reactivity to various PV L1 proteins
reactive to each HPV VLP type were selected for use as including HPV-6, -11, -16, -18, and -31, CRPV, and BPV-1.
control MAbs for the various VLPs that were used in Recombinant baculovirus-infected Sf9 cell lysates were
ELISA and Western blot studies as described below. separated on polyacrylamide gels and transferred to Im-
mobulon-P membranes as per the manufacturer’s in-ELISA reactivity to VLP and synthetic peptides
structions (Millipore, Bedford, MA). Membranes were
blocked for 2 hr in PBS containing 5% milk protein, thenThe specificity of the MAbs was tested in ELISA (Chris-
tensen et al., 1990) using a variety of different PV L1 incubated overnight in PBS–milk protein containing 1:50
final dilution of MAb supernatants. Membranes wereVLPs prepared from either recombinant baculoviruses
(HPV-6, -11, -16, -18, and -31, CRPV, and BPV-1) or recom- washed three times in PBS, then developed with alkaline
phosphatase-labeled anti-mouse antiserum (DAKO Corp.,binant vaccinia viruses (HPV-16, -33, -35, and -45). Intact
VLP antigen was attached to ELISA plate wells in PBS, Carpinteria, CA) and substrate.
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RESULTS The panel of 10 HPV-18 L1 VLP-reactive MAbs was
tested with a restricted set of PV L1 VLPs including HPV-
ELISA reactivity of MAbs to PV VLPs
6, -11, -16, -18, and -45 (Table 3). Four MAbs (H18.G10,
H18.J4, H18.K2, and H18.U15) were uniquely reactive toAll HPV-16 and -18 L1 VLP-reactive MAbs were tested
in ELISA using intact and denatured PV VLPs as de- surface conformational epitopes on HPV-18. Three MAbs
(H18.B1, H18.F8, and H18.R5) recognized a shared sur-scribed under Materials and Methods. VLPs containing
the L1 of HPV-6, -11, -16, -18, -31, -33, -35, and -45, CRPV, face conformational epitope located on HPV-18 and HPV-
45 L1 VLPs, and the remaining three MAbs (H18.E20,and BPV-1 were tested on the panel of 14 HPV-16 L1
VLP-reactive MAbs and the results are summarized in H18.L9, and H18.Q2) recognized a shared linear buried
epitope present on the L1 proteins of HPV-18 and -45.Tables 1 and 2. For the purposes of this article, conforma-
tional epitopes are operationally defined by MAbs that
bind to intact VLP by ELISA, but not to denatured VLP by Epitope mapping of MAbs using HPV-16 L1 20-amino-
ELISA or to L1 protein by Western blotting; linear epi- acid peptides
topes are operationally defined by MAbs that bind to
denatured VLPs in ELISA, as well as to L1 by Western The panel of HPV-16 L1 VLP-reactive MAbs was tested
for binding to a set of 35 overlapping 20-amino-acid syn-blotting; buried epitopes are operationally defined by
MAbs that bind to denatured VLP by ELISA but are nega- thetic peptides spanning the entire HPV-16 L1 protein as
described under Materials and Methods. Reactivity to ative for, or react very poorly to, intact VLP by ELISA.
Three MAbs (H16.E70, H16.U4, and H16.V5) were peptide sequence was detected for 9 of the 10 MAbs
that were reactive to denatured VLPs (Table 4). As pre-uniquely reactive to surface conformational epitopes on
intact HPV-16 L1 VLPs. One MAb (H16.P2) was weakly dicted, no reactivity to the peptides was observed for the
four MAbs that identified surface conformational epi-reactive to a shared conformational epitope present on
HPV-16, -31, and -35 L1 VLPs. Four MAbs (H16.C2, topes on intact VLPs (data not included). The nine reac-
tive MAbs identified five different peptide epitopes de-H16.H5, H16.L4, and H16.O7) were uniquely reactive to
a linear epitope on HPV-16 L1, and the remaining six fined as peptides A16-2, -10, -14, -20, and -29 (Dillner et
al., 1990), where A16-2 is at the amino terminus of L1MAbs were cross-reactive to various linear epitopes as
judged by positive ELISA reactivity to denatured VLP anti- and defines a region from amino acid 17 to 36, and pep-
tide A16-29 is toward the carboxy terminus and defines agen. Several of the MAbs that were reactive to linear
epitopes appeared to identify either surface linear epi- region from amino acid 422 to 441. Three MAbs (H16.C2,
H16.H5, and H16.O7) were reactive to peptide A16-14,topes (H16.H5, H16.I23, H16.J4, and H16.S1) as judged
by strong reactivity to both intact and denatured VLP, or and one MAb (H16.L4) was reactive to peptide A16-2.
Both these peptides appeared to have identified HPV-16buried linear epitopes (H16.B20, H16.C2, H16.D9,
H16.F18, H16.L4, and H16.O7) as judged by strong reac- type-specific linear epitopes as determined from ELISAs
using both VLP and peptide antigens (Tables 1, 2, andtivity to denatured VLP antigen but with minimal to weak
reactivity against intact VLP antigen. 4). The remaining MAbs were cross-reactive with various
PV L1s and identified peptides A16-29 (MAb H16.B20),Several MAbs were used as positive control reagents
for testing the integrity of the intact VLP preparations of A16-10 (MAbs H16.F18, H16.I23, and H16.S1), and A16-
20 (MAb H16.J4).the other PV L1 VLPs. These included H6.B10.5 for HPV-
6, H11.B2 for HPV-11, H18.R5 for HPV-18, H31.A6 for Peptides representing the homologous regions of sev-
eral other human and animal PVs were used to test theHPV-31, H33.E12 for HPV-33, H35.O3 for HPV-35, H45.C1
for HPV-45, CRPV-1A for CRPV, and B1.A1 for BPV-1. MAb specificity of the HPV-16-reactive MAbs. MAb H16.B20
was strongly reactive to homologous peptides from HPV-CRPV-10B, which recognized a surface linear epitope on
CRPV L1 VLPs, was also used to confirm the presence 11 and -31, and negative to the animal PV peptides from
CRPV and BPV-1. These data disagree somewhat withof denatured CRPV L1 VLPs since MAb CRPV-1A does
not react with denatured CRPV L1 VLP antigen. the VLP ELISA data (Table 1) with respect to reactivity
to HPV-31 in which this MAb appeared to be very weaklySeveral cross-reactive MAbs showed some interesting
patterns of reactivity to PV L1 proteins. For example, MAb reactive to denatured HPV-31 L1 VLPs. MAb H16.J4 also
showed some different reactivity patterns between ELI-H16.D9 was reactive to HPV-6, -11, -16, -31, and -35 and
CRPV, but was negative for reactivity to HPV-18, -33, and SAs using peptides and VLP. H16.J4 was strongly cross-
reactive with HPV-31 L1 in the VLP ELISA (and Western-45 and BPV-1. Another MAb, H16.J4, was reactive to HPV-
16, -31, -33, -35, and -45 and BPV-1, but was negative for blot), but was negative for reactivity to the HPV-31 homol-
ogous peptide (Tables 2 and 4).reactivity to HPV-6, -11, and -18 and CRPV. Neither of
these two reactivity patterns would have been predicted A limited set of HPV-18 L1 peptides was available to
test binding by the set of HPV-18 L1 VLP-reactive MAbs,by the relatedness of PVs as determined by their DNA
sequences (Chan et al., 1992; reviewed in Bernard et al., and only one MAb (H18.Q2) was found to be positive
for reactivity, which was to peptide A18-29. This peptide1994).
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FIG. 1. Western blot of reactivity of various HPV-16 L1-reactive MAbs. Tissue culture supernatants of MAbs (A) H16.B20, (B) H16.D9, (C) H16.F18,
(D) H16.H5, (E) H16.I23, and (F) H16.J4 at 1:50 dilution were tested for reactivity to Sf9 insect cell lysates (lane 8) and Sf9 cell lysates infected with
recombinant baculoviruses producing HPV-6 L1 (lane 1), HPV-11 L1 (lane 2), HPV-16 L1 (lane 3), HPV-18 L1 (lane 4), HPV-31 L1 (lane 5), BPV-1 L1
(lane 6), and CRPV L1 (lane 7). Molecular weight markers are shown on the left.
represented the HPV-18 L1 homologous region to pep- 18 L1 VLP in the ELISA because there was strong reactiv-
ity to this antigen by the MAb H16.F18 (Table 1).tide A16-29 of HPV-16 L1. Peptide A16-29 was recog-
nized by MAb H16.B20 (Table 1), but there was no cross-
DISCUSSIONreactivity between peptides A16-29 and A18-29 with re-
spect to the two MAbs, H16.B20 and H18.Q2, despite A panel of MAbs reactive to HPV-16 and -18 L1 VLPs
considerable conservation between these two peptides. was developed and screened for reactivity to a range of
different HPV L1 types. The MAbs recognized type-spe-Western blotting of selected HPV-16 L1 VLP-reactive
cific as well as cross-reactive linear and conformationalMAbs
capsid epitopes. The combination of antibody-binding
assays, which included Western blotting and ELISAs us-Several HPV-16 L1 VLP-reactive MAbs that reacted
with denatured PV VLPs in ELISA were tested for reactiv- ing intact VLP, denatured VLP, and synthetic peptides,
helped to define the nature of the epitopes recognizedity to various L1 proteins by Western blotting as de-
scribed under Materials and Methods. MAb H16.B20 by these MAbs. However, some discrepancies between
the VLP ELISA, the peptide ELISA, and Western blottingshowed reactivity to HPV-6, -11, -16, and -18 L1 but not
HPV-31, CRPV, or BPV-1 L1 (Fig. 1A). MAb H16.D9 were observed, and these results demonstrate that sev-
eral different assays are required to assess the full reac-showed reactivity to HPV-6, -11, -16, -18, and -31 and
CRPV L1 but not to BPV-1 L1 (Fig. 1B). MAb H16.F18 was tivity patterns of MAbs.
Epitopes recognized by 9 of 10 HPV-16-reactive MAbsreactive to HPV-16 and -18 L1 but not to HPV-6, -11, or
-31, CRPV, or BPV-1 L1 (Fig. 1C). MAb H16.H5 recognized that recognized denatured L1 were mapped using a set
of overlapping synthetic peptides spanning the entireonly HPV-16 L1 (Fig. 1D). MAb H16.I23 was reactive to
HPV-16, -18, and -31 L1, as well as to several insect cell HPV-16 L1 protein. Both surface and buried linear capsid
epitopes were identified using these MAbs and syntheticproteins, but was not reactive to HPV-6 or -11, CRPV, or
BPV-1 L1 (Fig. 1E). MAb H16.J4 was reactive to HPV16, peptides. Only one MAb (H16.D9) that was reactive to
denatured HPV-16 L1 by Western blotting did not react-18, and -31 and BPV-1, but was negative for reactivity to
HPV-6 or -11 or CRPV L1 (Fig. 1F). These data were in to any of the 35 HPV-16 L1 peptides. This MAb may
be able to recognize amino acids that span a site splitagreement with results obtained in the ELISAs for the
MAbs H16.F18, H16.H5, and H16.I23, but showed some between two peptides since the peptide overlap was
restricted to five amino acids.disagreements with the others. For example, the cross-
reactive MAbs H16.B20, H16.D9, and H16.J4 were all Five linear HPV-16 L1 epitopes were mapped by 9
MAbs, some of which recognized the same peptide. Pep-negative to denatured HPV-18 L1 VLP in ELISA, but were
weakly reactive to HPV-18 L1 by Western blotting. These tides A16-10 and A16-14 were recognized by two sets of
three different MAbs, respectively. Peptide A16-10 wasresults were not due to inadequate denaturation of HPV-
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recognized by MAbs H16.F18, H16.I23, and H16.S1, but ever, that the HPV-16 L1 VLP preparation that was first
used for immunizations and selection of MAbs showedELISA and Western reactivity patterns for these three
MAbs were not identical. MAbs H16.I23 and H16.S1 ap- signs of containing partly denatured antigen. Later ELI-
SAs that used freshly prepared HPV-16 L1 VLPs (Tablepeared to recognize a cross-reactive surface linear epi-
tope present on HPV-16, -18, -35, and -45 VLP, whereas 1) confirmed that some of the MAbs that were selected
in the initial screening were reactive to internal epitopes.MAb H16.F18 appeared to recognize a cross-reactive
buried linear epitope on the same HPV VLP types. MAb Such reactivities would not have been detected during
the first hybridoma screening assay if the initial batch ofH16.I23, but not MAbs H16.F18 and H16.S1, showed ad-
ditional reactivity to HPV-33 L1 as well as to several HPV-16 L1 VLPs had contained only intact VLP antigen.
As expected from previous studies (Christensen et al.,insect cell proteins as shown by Western blotting. These
results suggest that the three MAbs may have reacted 1990, 1994b; Roden et al., 1994b), several MAbs were
produced which recognized conformationally dependentto different regions of peptide A16-10. The outcome of a
more detailed analysis of peptide A16-10 and these three VLP type-specific epitopes. We have now developed
MAbs that recognized type-specific conformationally de-MAbs may demonstrate, for example, that one end of
this peptide sequence is buried within the capsid and the pendent epitopes for all HPV and animal PV types used
in this study. Previous studies have shown that manyother end exposed on the capsid surface. Alternatively,
different affinities of these three MAbs for the peptide type-specific conformationally dependent MAbs identi-
fied virus-neutralizing epitopes (Christensen et al., 1990,may explain why the peptide appeared to contain both
exposed and buried capsid epitopes. A similar situation 1994b; Roden et al., 1994b), and the expectation is that
some of the MAbs that were reactive to the high-riskoccurred with the three MAbs that recognized peptide
A16-14. All MAbs were reactive only to HPV-16 L1, but HPV types described in this study will also prove to be
neutralizing. These type-specific MAbs were highly reac-two of the MAbs (H16.C2 and H16.O7) indicated that this
region of L1 was buried, whereas the third MAb (H16.H5) tive to VLP antigen, and the high ELISA OD signals sug-
gest that they have high affinities and/or recognize multi-suggested that the epitope was surface located because
of a significant reactivity to intact VLP antigen in ELISA. ple epitopes per PV capsid (Roden et al., 1994b).
Two MAbs that were weakly reactive to intact VLPsSeveral research groups have defined linear epitopes
on HPV-16 L1 using monoclonal (Cason et al., 1989; were also obtained. These two MAbs (H16.P2 and
H18.B1) recognized a surface conformational epitope onMcLean et al., 1990) and polyclonal (Beiss et al., 1991;
Zhou et al., 1992; Heino et al., 1995b) antibodies, as well intact VLP which was also shared by closely related HPV
types. The weak reactivity was not due to low antibodyas antibodies from patients with HPV infections (Jenison
et al., 1991; Dillner et al., 1990; Cason et al., 1992). A titers, and the same VLP type that was prepared using
either recombinant vaccinia viruses or recombinant ba-range of different epitopes was detected and HPV-16
VLPs were used to assess whether the antibodies de- culoviruses was recognized equally. Because these two
MAbs did not show any binding activity to several otherfined capsid epitopes that were either surface located
or buried within the capsid (Zhou et al., 1992; Heino et human and animal PVs, or to denatured VLP, the epitope
that was recognized appeared to be viral in nature. Oneal., 1995b). These studies showed that antisera raised
to peptides 3, 8, 10, 14, 16, 20, 29, and 31 reacted to possible explanation for this weak but positive reactivity
is that these two MAbs recognized a limited number ofintact HPV-16 L1 VLPs by ELISA, with the major epitopes
defined by the antisera to peptides 14, 20, and 29 (Heino epitopes per capsid, and this possibility could be exam-
ined by EM studies using VLP and prebound MAb. Alter-et al., 1995b). The panel of MAbs generated in this study
identified linear epitopes to peptides 2, 10, 14, 20, and native explanations include a low affinity of these MAbs
or the possibility that abnormal forms of capsomere as-29. Three of these peptides (10, 14, and 20) appeared to
contain surface-located epitopes, while in the remaining sembly such as tubular structures (Volpers et al., 1994)
are present in the VLP antigen preparations at low con-two peptides (2 and 29), only epitopes buried within the
capsid were identified. The characterization of peptides centrations, and such structures may contain unique epi-
topes not found on correctly assembled capsids.10, 14, and 20 as containing surface linear epitopes using
the MAbs in this study, therefore, agreed with earlier Virus neutralization assays are not yet available to test
the neutralizing activity of the panel of HPV-16 and HPV-results using anti-peptide antisera and VLPs (Heino et
al., 1995b; Eklund and Dillner, 1995). 18 VLP-reactive MAbs. Several assays that may act as
surrogates for neutralization, such as antibody-mediatedSeveral MAbs that were reactive to HPV-16 L1 VLPs
recognized buried linear epitopes despite immunization prevention of HPV VLP-induced agglutination of mouse
red blood cells (RBC) (Roden et al., 1995), may help definewith intact VLP antigen. In contrast, most of the MAbs
generated against HPV-18 L1 VLP were reactive to sur- the neutralization capacity. Recent experiments have
shown that two of the HPV-16 L1 VLP MAbs (H16.E70face conformational epitopes, as found in our earlier MAb
studies using HPV-11 and CRPV (Christensen et al., 1990; and H16.V5) block HPV-16 VLP-induced agglutination of
mouse RBC (Roden et al., 1996), and these resultsChristensen and Kreider, 1991). We did observe, how-
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Chan, S.-Y., Bernard, H.-U., Ong, C.-K., Chan, S.-P., Hofmann, B., andstrongly suggest that these MAbs would neutralize HPV-
Delius, H. (1992). Phylogenetic analysis of 48 papillomavirus types16 infectivity. However, not all neutralizing MAbs prevent
and 28 subtypes and variants: A showcase for the molecular evolu-
VLP-induced agglutination of mouse RBC (Roden et al., tion of DNA viruses. J. Virol. 66, 5714–5725.
1995, 1996), and several of the MAbs described in this Christensen, N. D., and Kreider, J. W. (1991). Neutralization of CRPV
infectivity by monoclonal antibodies that identify conformational epi-study may prove to be neutralizing.
topes on intact virions. Virus Res. 21, 169–179.In summary, a panel of 24 MAbs reactive to HPV-16
Christensen, N. D., Kreider, J. W., Cladel, N. M., Patrick, S. D., andand -18 L1 VLP was prepared and examined for reactivity
Welsh, P. A. (1990). Monoclonal antibody-mediated neutralization of
to a panel of HPV L1 antigens and synthetic peptides. infectious human papillomavirus type 11. J. Virol. 64, 5678–5681.
Most of the MAbs reactive to linear epitopes were Christensen, N. D., Ho¨pfl, R., DiAngelo, S. L., Cladel, N. M., Patrick,
S. D., Welsh, P. A., Budgeon, L. R., Reed, C. A., and Kreider, J. W.mapped using the synthetic peptides, and various levels
(1994a). Assembled baculovirus-expressed human papillomavirusof cross-reactivity between human and animal PV L1 pro-
type 11 L1 capsid protein virus-like particles are recognized by neu-teins were observed. HPV-16 L1 type-specific linear and
tralizing monoclonal antibodies and induce high titres of neutralizing
conformationally dependent epitopes were identified. Ad- antibodies. J. Gen. Virol. 75, 2271–2276.
ditional MAbs reactive to type-specific, conformationally Christensen, N. D., Kirnbauer, R., Schiller, J. T., Ghim, S.-J., Schlegel,
R., and Kreider, J. W. (1994b). Human papillomavirus types 6 and 11dependent epitopes present on HPV-31, -33, -35, and -45
have antigenically distinct strongly immunogenic conformationallyL1 VLPs were also prepared. The MAbs should provide a
dependent neutralizing epitopes. Virology 205, 329–335.useful panel of reagents to map L1 epitopes of HPV-16
Cowsert, L. M., Lake, P., and Jenson, A. B. (1987). Topographical and
and -18 capsids, for quality control to probe HPV capsid conformational epitopes of bovine papillomavirus type 1 defined by
preparations for extent of degradation, as well as to map monoclonal antibodies. J. Natl. Cancer Inst. 79, 1053–1058.
Cubie, H. A. (1974). Experiments with human papilloma virus in cellneutralizing epitopes and viral structures that interact
culture. Br. J. Dermatol. 91, 569–571.with the host cell surface.
Devilliers, E. M. (1989). Papilloma viruses in cancers and papillomas
of the aerodigestive tract. Biomed. Pharmacother. 43, 31–36.
ACKNOWLEDGMENTS Dillner, J., Dillner, L., Utter, G., Eklund, C., Rotola, A., Costa, S., and
DiLuca, D. (1990). Mapping of linear epitopes of human papillomavi-This study was supported by Public Health Service Grants CA56460
rus type 16: The L1 and L2 open reading frames. Int. J. Cancer 45,(N.D.C.), CA42792 (D.A.G.), and AI38382 (D.A.G.), a grant from the Can-
529–535.cer Research Foundation of America (N.D.C.) and the Jake Gittlen Me-
Dollard, S. C., Wilson, J. L., Demeter, L. M., Bonnez, W., Reichman,morial Golf Tournament. We thank Drs. Ben Jenson (Georgetown Uni-
R. C., Broker, T. R., and Chow, L. T. (1992). Production of humanversity, Washington, DC) and John Schiller (NIH, Bethesda, MD) for the
papillomavirus and modulation of the infectious program in epithelialgenerous gifts of the recombinant baculovirus expressing HPV-6 and
raft cultures. Genes Dev. 6, 1131–1142.BPV-1 L1, respectively, and Kristin Robinson for purification of the re-
Eklund, C., and Dillner, J. (1995). A two-site enzyme immunoassay forcombinant vaccinia viruses.
quantitation of human papillomavirus type 16 particles. J. Virol. Meth-
ods 53, 11–23.
REFERENCES Favre, M., Breitburd, F., Croissant, O., and Orth, G. (1975). Structural
polypeptides of rabbit, bovine and human papillomaviruses. J. Virol.Beiss, B. K., Heimer, E., Felix, A., Burk, R. D., Ritter, D. B., Mallon, R. G.,
15, 1239–1247.and Kadish, A. S. (1991). Type-specific and cross-reactive epitopes in
Hagensee, M. E., Yaegashi, N., and Galloway, D. A. (1993). Self-assem-human papillomavirus type 16 capsid proteins. Virology 184, 460–
bly of human papillomavirus type 1 capsids by expression of the L1464.
protein alone or by coexpression of the L1 and L2 capsid proteins.Bernard, H.-U., Chan, S.-Y., and Delius, H. (1994). Evolution of papillo-
J. Virol. 67, 315–322.maviruses. Curr. Top. Microbiol. Immunol. 186, 33–54.
Hagensee, M. E., Olson, N. H., Baker, T. S., and Galloway, D. A. (1994).Bosch, F. X., Manos, M. M., Mun˜oz, N., Sherman, M., Jansen, A. M.,
Three-dimensional structure of vaccinia virus-produced human papil-Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shah, K. V., and
lomavirus type 1 capsids. J. Virol. 68, 4503–4505.the IBSCC Study Group. (1995). Prevalence of human papillomavirus
Heino, P., Dillner, J., and Schwartz, S. (1995a). Human papillomavirusin cervical cancer: A worldwide perspective. J. Natl. Cancer Inst. 87,
type 16 capsid proteins produced from recombinant Semliki forest796–802.
virus assemble into virus-like particles. Virology 214, 349–359.Brandsma, J. L., Brownstein, D. G., Xiao, W., and Longley, B. J. (1995).
Heino, P., Skyldberg, B., Lehtinen, M., Rantala, I., Hagmar, B., Kreider,Papilloma formation in human foreskin xenografts after inoculation
J. W., Kirnbauer, R., and Dillner, J. (1995b). Human papillomavirusof human papillomavirus type 16 DNA. J. Virol. 69, 2716–2719.
type 16 capsids expose multiple type-restricted and type-commonBreitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-
antigenic epitopes. J. Gen. Virol. 76, 1141–1153.Dinh-Desmarquet, C., Orth, G., Schiller, J. T., and Lowy, D. R. (1995).
Jenison, S. A., Yu, X.-P., Valentine, J. M., and Galloway, D. A. (1991).Immunization with viruslike particles from cottontail rabbit papillo-
Characterization of human antibody-reactive epitopes encoded bymavirus (CRPV) can protect against experimental CRPV infection. J.
human papillomavirus types 16 and 18. J. Virol. 65, 1208–1218.Virol. 69, 3959–3963.
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., and Schiller, J. T. (1992).Cason, J., Patel, D., Naylor, J., Lunney, D., Shepherd, P. S., Best, J. M.,
Papillomavirus L1 major capsid protein self-assembles into virus-and McCance, D. J. (1989). Identification of immunogenic regions of
like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USAthe major coat protein of human papillomavirus type 16 that contain
89, 12180–12184.type-restricted epitopes. J. Gen. Virol. 70, 2973–2987.
Kreider, J. W., Howett, M. K., Wolfe, S. A., Bartlett, G. L., Zaino, R. J.,Cason, J., Kambo, P. K., Best, J. M., and McCance, D. J. (1992). Detection
Sedlacek, T. V., and Mortel, R. (1985). Morphological transformationof antibodies to a linear epitope on the major coat protein (L1) of
in vivo of human uterine cervix with papillomavirus from condylomatahuman papillomavirus type-16 (HPV-16) in sera from patients with
acuminata. Nature 317, 639–641.cervical intraepithelial neoplasia and children. Int. J. Cancer 50, 349–
355. Kreider, J. W., Patrick, S. D., Cladel, N. M., and Welsh, P. A. (1990).
AID VY 8105 / 6a1d$$$343 08-03-96 19:56:44 vira AP: Virology
184 CHRISTENSEN ET AL.
Experimental infection with human papillomavirus type 1 of human rus (HPV) type 11 recombinant virus-like particles induce the forma-
tion of neutralizing antibodies and detect HPV-specific antibodies inhand and foot skin. Virology 177, 415–417.
human sera. J. Gen. Virol. 75, 2075–2079.Majewski, S., Breitburd, F., Skopinska, M., Croissant, O., Jablonska S.,
Sasagawa, T., Pushko, P., Steers, G., Gschmeissner, S. E., Hajibagheri,and Orth, G. (1994). A mouse model for studying epidermodysplasia –
M. A., Finch, J., Crawford, L., and Tommasino, M. (1995). Synthesisverruciformis-associated carcinogenesis. Int. J. Cancer 56, 727–730.
and assembly of virus-like particles of human papillomaviruses typeMcLean, C. S., Churcher, M. J., Meinke, J., Smith, G. L., Higgins, G.,
6 and type 16 in fission yeast Schizosaccharomyces pombe. VirologyStanley, A., and Minson, A. C. (1990). Production and characterisation
206, 116.of a monoclonal antibody to human papillomavirus type 16 using
Seedorf, K., Krammer, G., Durst, M., Suhai, S., and Rowekamp, W. G.recombinant vaccinia virus. J. Clin. Pathol. 43, 488–492.
(1985). Human papillomavirus type 16 DNA sequence. Virology 145,Meyers, C., Frattini, M. G., Hudson, J. B., and Laimins, L. A. (1992).
181–185.Biosynthesis of human papillomavirus from a continuous cell line
Sterling, J., Stanley, M., Gatward, G., and Minson, T. (1990). Productionupon epithelial differentiation. Science 257, 971–973.
of human papillomavirus type 16 virions in a keratinocyte cell line.Mu¨ller, M., Gissmann, L., Cristiano, R. J., Sun, X.-Y., Frazer, I. H., Jenson,
J. Virol. 64, 6305–6307.A. B., Alonso, A., Zentgraf, H., and Zhou, J. (1995). Papillomavirus
Taichman, L. B., Breitburd, F., Croissant, O., and Orth, G. (1984). Thecapsid binding and uptake by cells from different tissues and spe-
search for a culture system for papillomaviruses. J. Invest. Dermatol.cies. J. Virol. 69, 948–954.
83, 2s–6s.Roden, R. B. S., Kirnbauer, R., Jenson, A. B., Lowy, D. R., and Schiller,
Volpers, C., Schirmacher, P., Streeck, R. E., and Sapp, M. (1994). Assem-J. T. (1994a). Interaction of papillomaviruses with the cell surface. J.
bly of the major and the minor capsid protein of human papillomavi-
Virol. 68, 7260–7266.
rus type 33 into virus-like particles and tubular structures in insect
Roden, R. B. S., Weissinger, E. M., Henderson, D. W., Booy, F., Kirnbauer, cells. Virology 200, 504.
R., Mushinski, J. F., Lowy, D. R., and Schiller, J. T. (1994b). Neutraliza- Volpers, C., Unckell, F., Schirmacher, P., Streeck, R. E., and Sapp, M.
tion of bovine papillomavirus by antibodies to L1 and L2 capsid (1995). Binding and internalization of human papillomavirus type 33
proteins. J. Virol. 68, 7570–7574. virus-like particles by eukaryotic cells. J. Virol. 69, 3258–3264.
Roden, R. B. S., Hubbert, N. L., Kirnbauer, R., Breitburd, F., Lowy, D. R., Zhou, J., Sun, X. Y., Stenzel, D. J., and Frazer, I. H. (1991). Expression
and Schiller, J. T. (1995). Papillomavirus L1 capsids agglutinate of vaccinia recombinant HPV-16 L1 and L2 ORF proteins in epithelial
mouse erythrocytes through a proteinaceous receptor. J. Virol. 69, cells is sufficient for assembly of HPV virion-like particles. Virology
5147–5151. 185, 251–257.
Roden, R. B. S., Hubbert, N. L., Kirnbauer, R., Christensen, N. D., Lowy, Zhou, J., Sun, X.-Y., Davies, H., Crawford, L., Park, D., and Frazer, I. H.
D. R., and Schiller, J. T. (1996). Assessment of the serological relat- (1992). Definition of linear antigenic regions of the HPV16 L1 capsid
edness of genital human papillomaviruses by hemagglutination inhi- protein using synthetic virion-like particles. Virology 189, 592–599.
bition. J. Virol. 70, 3298–3301. zur Hausen, H. (1991). Human papillomaviruses in the pathogenesis
of anogenital cancer. Virology 184, 9–13.Rose, R. C., Reichman, R. C., and Bonnez, W. (1994). Human papillomavi-
AID VY 8105 / 6a1d$$$344 08-03-96 19:56:44 vira AP: Virology
